{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.3"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4"}]}],"title":"Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1"}]}],"title":"Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Estimate of the incidence of non-hematologic regimen-related toxicity and regimen-related toxicity in the first 100 days post-transplant. The percentage of participants are reported by maximum grade seen using binomial distribution. Participants were graded for toxicity using Common Terminology Criteria for Adverse Events version 3.0. In general, Grade 1 is mild, 2 is moderate toxicity but generally does not require treatment, 3 is severe enough to require treatment, 4 is life-threatening, and 5 means it was associated with death.","groups":[{"description":"Participants meeting eligibility criteria and who underwent haploidentical stem cell transplantation with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (beginning January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.","id":"OG000","title":"High-Risk Hematologic Malignancies"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days post-transplant","title":"Incidence of Non-hematologic Regimen-related Toxicities","type":"SECONDARY","unitOfMeasure":"percentage of participants"}